Ivosidenib Now FDA-Approved as First-Line Treatment for AML with IDH1 Mutation

Web Exclusives - FDA Approvals, News & Updates, In the News

On May 2, 2019, the US Food and Drug Administration (FDA) approved ivosidenib (Tibsovo; Agios Pharmaceuticals, Inc) for the treatment of newly diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved companion diagnostic test, in patients who are aged ≥75 years or who have comorbidities that preclude the use of intensive induction chemotherapy.

This is the second FDA approval for ivosidenib, which was previously approved on July 20, 2018, for the treatment of patients with relapsed or refractory AML with a susceptible IDH1 mutation.

The most recent approval of this agent was based on results from the open-label, single-arm, multicenter, clinical trial that included 28 patients with newly diagnosed AML with an IDH1 mutation.

Patients were treated with ivosidenib, which was administered orally at a dose of 500 mg daily until disease progression, development of unacceptable toxicity, or stem-cell transplantation. The primary end point of the trial was the combined complete remission (CR) and complete remission with partial hematologic improvement (CRh) rate.

Twelve (42.9%) of the 28 patients achieved CR+CRh, and 7 (41.2%) of the 17 transfusion-dependent patients achieved transfusion independence lasting ≥8 weeks. Two of the 28 patients underwent stem-cell transplantation following ivosidenib treatment.

Adverse reactions occurring in ≥25% of patients included diarrhea, fatigue, edema, decreased appetite, leukocytosis, nausea, arthralgia, abdominal pain, dyspnea, differentiation syndrome, and myalgia.

The prescribing information for ivosidenib includes a boxed warning that differentiation syndrome may occur and can be fatal if not treated.

Related Items
FDA Expands Indication for Kadcyla to Include the Adjuvant Treatment of HER2-Positive Early Breast Cancer
Web Exclusives published on May 14, 2019 in Breast Cancer, FDA Approvals, News & Updates, In the News
FDA News
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in FDA Approvals, News & Updates
FDA Approves Pembrolizumab plus Axitinib for Advanced Renal-Cell Carcinoma
Web Exclusives published on April 23, 2019 in FDA Approvals, News & Updates, In the News, Renal-Cell Carcinoma
April 16, 2019 – FDA Approvals, News & Updates
Web Exclusives published on April 16, 2019 in FDA Approvals, News & Updates, In the News, Lung Cancer
FDA Approves First Hormonal-Based Therapy for Men with Advanced or Metastatic Breast Cancer
Web Exclusives published on April 5, 2019 in Breast Cancer, FDA Approvals, News & Updates, In the News
Proposed Landmark Policy Changes to Modernize Mammography and Raise Breast Density Awareness
Web Exclusives published on April 1, 2019 in Breast Cancer, FDA Approvals, News & Updates, In the News
FDA Approves Tecentriq plus Chemotherapy for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer
Web Exclusives published on March 22, 2019 in FDA Approvals, News & Updates, In the News, Lung Cancer
FDA Approves Tecentriq plus Abraxane—First Immunotherapy for PD-L1– Positive Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Web Exclusives published on March 15, 2019 in FDA Approvals, News & Updates, In the News
March 08, 2019 – FDA Approvals, News & Updates
Web Exclusives published on March 8, 2019 in FDA Approvals, News & Updates, In the News
FDA Approves Pembrolizumab for Treatment of Advanced Melanoma
Web Exclusives published on February 22, 2019 in FDA Approvals, News & Updates, In the News
Last modified: May 6, 2019